1 |
Christman, M. F., F. S. Dietrich and G. R. Frink. 1988. Mitotic recombination in the rRNA of S.cerevisiae is suppressed by the combined action of to po I and II. Cell 55, 413-425.
DOI
ScienceOn
|
2 |
Jeong, I. C. and M. Y. Cho. 2006. Analysis of gene expression profile in 10-hydroxycamptothecin-treated human leukemia HL-60 cells using oligonucleotide microarray. Kosin Medical J. 21, 338-343.
|
3 |
Jeong, J. C. and M. Y. Cho. 2006. Effects of irinotecan on the activity and expression of topoisomerase I and III in HL-60 human leukemia cells. Kosin Medical J. 21, 344-348.
|
4 |
Jeong, I. C., D. S. Jung, K. J. Ryu, J. S. Park and M. Y. Cho. 2000. Effects of camptothecin on the expression of DNA topoisomerase I and c-myc in HL-60 human leukemia cells. J. Life Sci. 10, 621-629.
과학기술학회마을
|
5 |
Jeong, I. C., N. J. Lee, S. U. Lee, S. J. Lee and M. Y. Cho. 2004. Expression profile of topoisomerase, ras and myc genes in HL-60 cells treated with camptothecin. Kosin Medical J. 19, 271-278.
|
6 |
Wang, J. C. 1987. Recent studies of DNA topoisomerases. Biochim. Biophys. Acta. 909, 1-9.
DOI
ScienceOn
|
7 |
Stahl, M., S. Kasimir-Bauer and A. Harstrick. 1997. Down-regulation of topoisomerase II by camptothecin does not prevent additive activity of the topoisomerase II inhibitor etoposide in vitro. genes in human breast cancers. Anticancer Drugs 8, 671-676.
DOI
ScienceOn
|
8 |
Pu, Q. Q. and W. R. Bezwoda. 1999. Induction of alkylator (melphalan) resistance in HL60 cells is accompanied by increased levels of topoisomerase II expression and function. Mol. Pharmacol. 56, 147-153.
DOI
|
9 |
Wall, M. E., M. C. Wani, C. E. Cook, K. H. Palmer, A. T. McPhail and G. A. Sim. 1966. Plant antitumor agents. I. The isolation and structure of camptothecin, a novel alkaloidal leukemia and tumor. J. Am. Chem. Soc. 88, 3888-3890.
DOI
|
10 |
Thielmann, H. W. and O. Popanda. 1998. Doxorubicin and gamma rays increase the level of DNA topoisomerase II alpha in nuclei of normal and xeroderma pigmentosum fibroblasts. J. Cancer Res. Clin. Oncol. 124, 355-366.
DOI
ScienceOn
|
11 |
Wang, J, J. Medeiros, D. L. Longo, A. Mansoor, M. Raffeld, P. I. Duffey, E. S. Jaffe and M. S. Stevenson. 1996. Use of the polymerase chain reaction technique to determine c-myc expression in follicular center cell lymphoma. Diagnostic Mol. Pathol. 5, 20-25.
DOI
ScienceOn
|
12 |
Wang, J. C. 1985. DNA topoisomerases, Annu. Rev. Biochem. 54, 665-697.
DOI
ScienceOn
|
13 |
Guo, X., J. Zhang, X. Fu, Q. Wei, Y. Lu, Y. Li, G. Yin, Y. Mao, Y. Xie, Y. Rui and K. Ying. 2006. Analysis of common gene expression patterns in four human tumor cell lines exposed to amptothecin using cDNA microarray: identification of topoisomerase-mediated DNA damage response pathways. Front Biosci. 1, 1924-1931.
|
14 |
Clary, A, A. Larrue, P. Pourquier and J. Robert. 1998. Transcriptional down- regulation of c-myc expression in an erythroleukemic cell line, K562, and its doxorubicin-resistant variant by two topoisomerase II inhibitors, doxorubicin and amsacrine. Anticancer Drugs 9, 245-254.
DOI
|
15 |
Champoux, J.J. 2001. DNA topoisomerases: structure, function, and mechanism. Annu. Rev. Biochem. 70, 369-413.
DOI
ScienceOn
|
16 |
Chen, S., S. P. Gomez, D. McCarley and M. G. Mainwaring. 2002. Topotecan-induced topoisomerase II alpha expression increases the sensitivity of the CML cell line K562 to subsequent etoposide plus mitoxantrone treatment. Cancer Chemother. Pharmacol. 49, 347-355.
DOI
ScienceOn
|
17 |
Cho, M. Y. and J. C. Jeong. 2004. Effects of doxorubicin on the activity and expression of topoisomerase in HL-60 human leukemia cells. Kosin Medical J. 19, 286-293.
|
18 |
Fornari, F. A., D. W. Jarvis, S. Grant, M. S. Orr, J. K. Randolph, F. K. White and D. A. Gewirtzm. 1996. Growth arrest and non-apoptotic cell death associated with the suppression of c-myc expression in MCF-7 breast tumor cells following acute exposure to doxorubicin. Biochem. Pharmacol. 51, 931-940.
DOI
ScienceOn
|
19 |
Zhou, Y., F. G. Gwadry, W. C. Reinhold, L. D. Miller, L. H. Smith, U. Scherf, E. T. Liu, K. W. Kohn, Y. Pommier and J. N. Weinstein. 2002. Transcriptional regulation of mitotic genes by camptothecin-induced DNA damage: microarray analysis of dose- and time-dependent effects. Cancer Res. 62, 1688-1695.
|
20 |
Xu, J. M., A. Azzariti, S. Tommasi, R. Lacalamita, G. Colucci, P. G. Johnston, S. W. Church and A. Paradiso. 2002. Combination of 5-fluorouracil and irinotecan on modulation of thymidylate synthase and topoisomerase I expression and cell cycle regulation in human colon cancer LoVo cells: clinical relevance. Clin. Colorectal Cancer 2, 182-188.
DOI
ScienceOn
|
21 |
Kazuya, K., R. Manasi, R. Roald, G. E. Abdel, L. B. Michael, S. M. Paul, M. T. Jeffrey, S. D. William and V. C. Khew, 2000. Monitoring the expression profiles of doxorubicin-induced and doxorubicin-resistant cancer cells by cDNA microarray. Cancer Res. 60, 4161-4166.
|
22 |
Schomburg, U. and F. Grosse. 1986. Purification and characterization of DNA topoisomerase II from calf thymus associated with polypeptides of 175 and 150 kDa. Eur. J. Biochem. 160, 451-457.
DOI
ScienceOn
|
23 |
Sandri, M. I., D. Hochhauser, P. Ayton, R. C. Camplejohn, R. Whitehouse, H. Turley, K. Gatter, I. D. Hickson and A. L. Harris, 1996. Differential expression of the topoisomerase II alpha and beta. Br. J. Cancer 73, 1518-1524.
DOI
|
24 |
Orr, M. S., F. A. Fornari, J. K. Randolph and D. A. Gewirtz. 1995. Transcriptional down-regulation of c-myc expression in the MCF-7 breast tumor cell line by the topoisomerase II inhibitor, VM-26. Biochim. Biophys. Acta. 1262, 139-145.
DOI
ScienceOn
|
25 |
Jain, P. T., F. A. Fornari, J. K. Randolph, M. S. Orr and D. A 1998. Gewirtz. Induction of DNA damage, inhibition of DNA synthesis, and suppression of c-myc expression by the topoisomerase I inhibitor, camptothecin, in MCF-7 human breast tumor cells. Biochem. Pharmacol. 55, 1263-1269.
DOI
ScienceOn
|
26 |
Nair, J., F. Traganos and Y. C. Tse-Dinh. 2000. Differential effect of camptothecin treatment on topoisomerase II alpha expression in ML-1 and HL-60 leukemia cell lines. Anticancer Res. 20, 4183-4188.
|
27 |
Liu, L. F. 1989. DNA topoisomerase poisons as antitumor drugs. Annu. Rev. Biochem. 58, 351-375.
DOI
ScienceOn
|
28 |
Perego, P., G. Capranico, R. Supino and F. Zunino. 1994. Topoisomerase I gene expression and cell sensitivity to camptothecin in human cel1 lines of different tumor types. Anticancer Drugs 5, 645-649.
DOI
ScienceOn
|
29 |
Kersting, G., M. V. Tzvetkov, K. Huse, B. Kulle, V. Hafner, J. Brockmoller and L. Wojnowski. 2006. Topoisomerase II beta expression level correlates with doxorubicin-induced apoptosis in peripheral blood cells. Naunyn Schmiedebergs Arch. Pharmacol. 374, 21-30.
DOI
ScienceOn
|
30 |
John, M., A. Diego, S. Qiuhu, J. W. Andrew, A. C. Georgia, N. Courtney, J. A. Maria, L. Martin, L. S. Edward and H. A. Leonard. 2003. Gene expression profiling-based prediction of response of colon carcinoma cells to 5-fluorouracil and camptothecin. Cancer Res. 63, 8791-8812.
|